Interleukin 6 and complement serum level study in Parkinson’s disease

  • Branislav Veselý
  • Michal Dufek
  • Vojtech Thon
  • Miroslav Brozman
  • Silvia Királová
  • Tatiana Halászová
  • Eva Koriťáková
  • Ivan Rektor
Neurology and Preclinical Neurological Studies - Original Article
  • 31 Downloads

Abstract

The objective of this study is to assess whether elevation of serum inflammatory markers levels may indicate the progression of clinical impairment in Parkinson’s disease (PD) patients. In 47 PD patients, the serum levels of the C3 and C4 part of the complement and Interleukin-6 (IL-6) were measured. The results at baseline and after 2 years were correlated with scales measuring memory, depression, motor symptoms, and quality of life. Patients with higher levels of C3 and C4 at baseline had decreased quality of life, verbal ability, and memory. Patients with higher IL-6 at baseline showed worse depression scores at 2 years. Patients with persistently higher levels of C3 and C4 at 2 years had worse quality of life and memory ability. Uncorrected p values are reported due to the exploratory nature of the study. The results indicate an impact of inflammation on non-motor signs and quality of life in PD. The increase of levels of serum inflammatory biomarkers may indicate the progression of non-motor impairment in PD.

Keywords

Complement Interleukin 6 Parkinson’s disease 

Abbreviations

ACE

Addenbrooke’s cognitive examination

ADL

Activity of Daily Living Scale

BI

Barthel Index

BVRT

Benton visual retention test

CDT

Clock drawing test

CSF

Cerebrospinal fluid

ECLIA

Electrochemiluminescence immunoassay

H–Y

Hoehn–Yahr Scale

IL-6

Interleukin 6

MADRS

Montgomery Asberg Depression Rating Scale

MMSE

Mini-mental state examination

PD

Parkinson’s disease

UPDRS

Unified Parkinson’s Disease Rating Scale

VFT

Verbal fluency test

WMS

Wechsler Memory Scale

Notes

Acknowledgements

We would like to thank to Prof. Egon Kurča, M.D., Ph.D., FESO, Prof. Peter Valkovič, M.D., Ph.D., and Ján Necpal, M.D., for kindly referring their patients for participation in this study and to Anne Johnson for grammatical assistance.

Author contributions

BV: research project: conception, organization, execution; statistical analysis: review and critique; manuscript: writing of the first draft. MD: research project: execution; manuscript: review and critique. VT: research project: execution; manuscript: review and critique. EK: statistical analysis: design, execution, review and critique. MB: research project: execution. SK: research project: execution. TH: research project: execution. IR: research project: conception, organization, execution; statistical analysis: design; manuscript: review and critique.

Compliance with ethical standards

Conflict of interest

None of the authors report any conflict of interest or financial disclosure.

References

  1. Auriacombe S, Grossman M, Carvell S, Gollomp S (1993) Verbal fluency deficits in Parkinson’s disease. Neuropsychology 7:182–192CrossRefGoogle Scholar
  2. Benton AL (1983) Contributions to neuropsychological assessment. Oxford University Press, New YorkGoogle Scholar
  3. Berczi I, Quintanar-Stephano A, Kovacs K (2009) Neuroimmune regulation in immunocompetence, acute illness, and healing. Ann N Y Acad Sci 1153:220–239CrossRefPubMedGoogle Scholar
  4. Bonifati DM, Kishore U (2007) Role of complement in neurodegeneration and neuroinflammation. Mol Immunol 44:999–1010CrossRefPubMedGoogle Scholar
  5. Brodacki B, Staszewski J, Toczyłowska B, Kozłowska E, Drela N, Chalimoniuk M, Stepien A (2008) Serum interleukin (IL-2, IL-10, IL-6, IL-4), TNF-alpha, and IFNgamma concentrations are elevated in patients with atypical and idiopathic parkinsonism. Neurosci Lett 441:158–162CrossRefPubMedGoogle Scholar
  6. Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW (2008) From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci 9:46–56CrossRefPubMedPubMedCentralGoogle Scholar
  7. Dobbs RJ, Charlett A, Purkiss AG, Dobbs SM, Weller C, Peterson DW (1999) Association of circulating TNF-alpha and IL-6 with aging and parkinsonism. Acta Neurol Scand 100:34–41CrossRefPubMedGoogle Scholar
  8. Dufek M, Hamanová M, Lokaj L, Goldemund D, Rektorová I, Michálková Z, Sheardová K, Rektor I (2009) Serum inflammatory biomarkers in Parkinson’s disease. Parkinsonism Relat Disord 15:318–320CrossRefPubMedGoogle Scholar
  9. Dufek M, Rektorová I, Thon V, Lokaj L, Rektor I (2015) Interleukin-6 may contribute to mortality in Parkinson’s disease patients: a 4 year prospective study. Parkinson’s Dis 2015:898192Google Scholar
  10. Dunn AJ (2006) Effects of cytokines and infections on brain neurochemistry. Clin Neurosci Res 6:52–68CrossRefPubMedPubMedCentralGoogle Scholar
  11. Fahn S, Elston RL, Members of the UPDRS Development Committee (1987) Unified Parkinson’s disease rating scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB (eds) Recent developments in Parkinson’s disease, vol 2. Macmillan, New York, pp 153–163Google Scholar
  12. Finehout EJ, Franck Z, Lee KH (2005) Complement proteins isoforms in CSF as possible biomarkers for neurodegenerative diseases. Dis Markers 11:93–101CrossRefGoogle Scholar
  13. Folstein MF, Folstein SE, McHugh PR (1975) “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189–198CrossRefPubMedGoogle Scholar
  14. Freedman M, Kaplan E, Delis D, Morris R (1994) Clock drawing: a neuropsychological analysis. Oxford University Press, New YorkGoogle Scholar
  15. Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17:427–442CrossRefPubMedGoogle Scholar
  16. Hoffmann KW, Schuh Schumacher AF, SauteJ Townsend R, Fricke D, Leke R, Souza DO, Valmor Portela L, Fagundes Chaves ML, Rieder CRM (2009) Interleukin-6 serum levels in patients with Parkinson’s disease. Neurochem Res 34:1401–1404CrossRefGoogle Scholar
  17. Honglei C, Shumin M, Ascherio A (2003) Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol 60:1059–1064CrossRefGoogle Scholar
  18. Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181–184CrossRefPubMedPubMedCentralGoogle Scholar
  19. Kang Sujin, Tanaka Toshio, Kishimoto Tadamitsu (2015) Therapeutic uses of anti-interleukin-6 receptor antibody. Int Immunol 27(1):21–29CrossRefPubMedGoogle Scholar
  20. Lawton MP, Brody EM (1969) Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist 9:179–186CrossRefPubMedGoogle Scholar
  21. Lindqvist D, Kaufman E, Brundin L, Hall S, Surova Y, Hansson O (2012) Nonmotor symptoms in patients with Parkinson’s disease—correlations with inflammatory cytokines in serum. PLoS One 7:e47387CrossRefPubMedPubMedCentralGoogle Scholar
  22. Lindqvist D, Hall S, Surova Y, Nielsen HM, Janelidze S, Brundin L, Hansson O (2013) Cerebrospinal fluid inflammatory markers in Parkinson’s disease-associations with depression, fatigue, and cognitive impairment. Brain Behav Immun 33:183–189CrossRefPubMedGoogle Scholar
  23. Mahoney FI, Barthel DW (1965) Functional evaluation: the BARTHEL index. MD State Med J 14:61–65PubMedGoogle Scholar
  24. Mogi M, Harada M, Kondo T, Riederer P, Inagaki H, Minami M, Nagatsu T (1994) Interleukin-1beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci Lett 180:147–150CrossRefPubMedGoogle Scholar
  25. Mogi M, Harada M, Narabayashi H, Inagaki H, Minami M, Nagatsu T (1996) Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming factor levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson’s disease. Neurosci Lett 211:13–16CrossRefPubMedGoogle Scholar
  26. Montgomery SA, Asberg MA (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382–389CrossRefPubMedGoogle Scholar
  27. Müller T, Blum-Degen D, Przuntek H, Kuhn W (1998) Interleukin-6 levels in cerebrospinal fluid inversely correlate to severity of Parkinson’s disease. Acta Neurol Scand 98:142–144CrossRefPubMedGoogle Scholar
  28. Olson KE, Gendelman HE (2016) Immunomodulation as a neuroprotective and therapeutic strategy for Parkinson’s disease. Curr Opin Pharmacol 26:87–95CrossRefPubMedGoogle Scholar
  29. Pålhagen S, Qi H, Mårtensson B, Wålinder J, Granérus AK, Svenningsson P (2010) Monoamines, BDNF, IL-6 and corticosterone in CSF in patients with Parkinson’s disease and major depression. J Neurol 257:524–532CrossRefPubMedGoogle Scholar
  30. Qin XY, Zhang SP, Cao C, Loh YP, Cheng Y (2016) Aberrations in peripheral inflammatory cytokine levels in Parkinson’s disease: a systematic review and meta-analysis. JAMA Neurol 73:1316–1324CrossRefPubMedGoogle Scholar
  31. Reyes MA, Perez-Lloret SP, Roldan Gerscovich EG, Martin ME, Leiguarda R, Merello M (2009) Addenbrooke’s Cognitive Examination validation in Parkinson’s disease. Eur J Neurol 16:142–147CrossRefPubMedGoogle Scholar
  32. Santangelo G, Vitale C, Picillo M, Moccia M, Cuoco S, Longo K, Barone P (2015) Mild Cognitive Impairment in newly diagnosed Parkinson’s disease: a longitudinal prospective study. Parkinsonism Relat Disord 21:1219–1226CrossRefPubMedGoogle Scholar
  33. Scalzo P, Kümmer A, Cardoso F, Teixeira AL (2010) Serum levels of interleukin-6 are elevated in patients with Parkinson’s disease and correlate with physical performance. Neurosci Lett 468:56–58CrossRefPubMedGoogle Scholar
  34. Schwab C, Steele JC, McGeer PL (1996) Neurofibrillary tangles of Guam Parkinson-dementia are associated with reactive microglia and complement proteins. Brain Res 707:196–205CrossRefPubMedGoogle Scholar
  35. Umemura A, Oeda T, Yamamoto K (2015) Baseline plasma C-reactive protein concentrations and motor prognosis in Parkinson disease. PLoS One 10(8):0136722Google Scholar
  36. Wechsler D (1997) Wechsler memory scale the third edition, WMS-III. The Psychological Corporation, San AntonioGoogle Scholar
  37. Williams-Gray CH, Wijeyekoon R, Yarnall AJ, Lawson RA, Breen DP, Evans JR, ICICLE-PD Study Group et al (2016) Serum immune markers and disease progression in an incident Parkinson’s disease cohort (ICICLE-PD). Mov Disord 31(7):995–1003CrossRefPubMedPubMedCentralGoogle Scholar
  38. Yamada T, McGeer PL, McGeer EG (1992) Lewy bodies in Parkinson’s disease recognized by antibodies to complement proteins. Acta Neuropathol 84:100–104CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Austria, part of Springer Nature 2018

Authors and Affiliations

  • Branislav Veselý
    • 1
    • 3
  • Michal Dufek
    • 2
  • Vojtech Thon
    • 4
  • Miroslav Brozman
    • 1
  • Silvia Királová
    • 5
  • Tatiana Halászová
    • 5
  • Eva Koriťáková
    • 6
  • Ivan Rektor
    • 2
    • 3
  1. 1.Department of Neurology, Faculty HospitalConstantine the Philosopher UniversityNitraSlovak Republic
  2. 2.Movement Disorders Center, First Department of NeurologyMasaryk University, St. Anne’s University HospitalBrnoCzech Republic
  3. 3.Central European Institute of Technology (CEITEC), Brain and Mind Research ProgrammeBrnoCzech Republic
  4. 4.Department of Clinical Immunology and Allergy, Faculty of MedicineMasaryk University, St. Anne’s University HospitalBrnoCzech Republic
  5. 5.Department of Clinical Psychology, Faculty HospitalConstantine the Philosopher UniversityNitraSlovak Republic
  6. 6.Institute of Biostatistics and Analyses, Faculty of MedicineMasaryk UniversityBrnoCzech Republic

Personalised recommendations